GLAUCOMA: Edited by Donald L. BudenzReview of the Xen Gel Stent and InnFocus MicroShuntGreen, Wesley; Lind, John T.; Sheybani, ArshamAuthor Information Department of Ophthalmology and Visual Sciences, Washington University School of Medicine in Saint Louis, Saint Louis, Missouri, USA Correspondence to Dr. Arsham Sheybani, MD, Department of Ophthalmology and Visual Sciences, Washington University School of Medicine in Saint Louis, 660 South Euclid Avenue, Campus Box 8096, Saint Louis, MO 63110, USA. Tel: +1 314 362 3937; E-mail: [email protected] Current Opinion in Ophthalmology: March 2018 - Volume 29 - Issue 2 - p 162-170 doi: 10.1097/ICU.0000000000000462 Buy Metrics Abstract Purpose of review Two new translimbal glaucoma devices (Xen Gel Stent and InnFocus MicroShunt) have been developed with the goal of optimizing the predictability and safety for subconjunctival glaucoma surgery. Recent findings The new subconjunctival glaucoma implants are manufactured from nonsilicone, biocompatible materials, which may reduce the postoperative inflammatory and fibrotic reactions that can lead to failure. Early data suggests a favorable safety profile with significant reductions in intraocular pressure (IOP). The prevention of chronic hypotony has been a hallmark of the devices, which utilize an intrinsic flow-limiting design based on the tube length and internal lumen diameter. Summary Early data with the XEN Gel Stent and InnFocus MicroShunt show promising results. Prospective comparative studies comparing these devices with tube shunt and trabeculectomy will be needed. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.